P Cassano

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos
    Paolo Cassano
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, United States
    J Affect Disord 150:578-84. 2013
  2. doi request reprint Major depressive disorder with psychosis-like symptoms among Latinos
    Paolo Cassano
    Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, Sixth Floor, Boston, MA 02114, USA
    Psychiatr Serv 63:482-7. 2012
  3. ncbi request reprint Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine
    Paolo Cassano
    The Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 74:362-5. 2005
  4. ncbi request reprint Pramipexole in treatment-resistant depression: an extended follow-up
    Paolo Cassano
    Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy
    Depress Anxiety 20:131-8. 2004
  5. ncbi request reprint Ropinirole in treatment-resistant depression: a 16-week pilot study
    Paolo Cassano
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Can J Psychiatry 50:357-60. 2005
  6. ncbi request reprint Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine
    P Cassano
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, U S A
    Arch Womens Ment Health 7:167-71. 2004
  7. ncbi request reprint Tolerability issues during long-term treatment with antidepressants
    Paolo Cassano
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 16:15-25. 2004
  8. ncbi request reprint Pramipexole in treatment-resistant depression: a 16-week naturalistic study
    Lorenzo Lattanzi
    Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Italy
    Bipolar Disord 4:307-14. 2002
  9. ncbi request reprint Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder
    Lee S Cohen
    Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital MGH, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:540-3. 2004
  10. ncbi request reprint Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Nerv Ment Dis 195:175-8. 2007

Detail Information

Publications20

  1. pmc Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos
    Paolo Cassano
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, United States
    J Affect Disord 150:578-84. 2013
    ....
  2. doi request reprint Major depressive disorder with psychosis-like symptoms among Latinos
    Paolo Cassano
    Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, Sixth Floor, Boston, MA 02114, USA
    Psychiatr Serv 63:482-7. 2012
    ....
  3. ncbi request reprint Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine
    Paolo Cassano
    The Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 74:362-5. 2005
    ..We assessed the impact of menopausal status on treatment response and well-being in a cohort of outpatient women with major depressive disorder (DSM-III-R criteria), who received treatment with fluoxetine (20 mg/day for 8 weeks)...
  4. ncbi request reprint Pramipexole in treatment-resistant depression: an extended follow-up
    Paolo Cassano
    Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy
    Depress Anxiety 20:131-8. 2004
    ..Pramipexole augmentation of antidepressant treatment was relatively safe and presumably effective in the long-term course of treatment resistant depression...
  5. ncbi request reprint Ropinirole in treatment-resistant depression: a 16-week pilot study
    Paolo Cassano
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Can J Psychiatry 50:357-60. 2005
    ..The study aimed to assess the antidepressant efficacy and tolerability of adjunctive ropinirole in outpatients with treatment-resistant depression (TRD)...
  6. ncbi request reprint Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine
    P Cassano
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, U S A
    Arch Womens Ment Health 7:167-71. 2004
    ..To examine sex- and age-related differences of treatment outcome in a cohort of outpatients with major depressive disorder (MDD), with and without comorbid anxiety, treated with fluoxetine...
  7. ncbi request reprint Tolerability issues during long-term treatment with antidepressants
    Paolo Cassano
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 16:15-25. 2004
    ..Therefore, clinicians are likely to prefer them in usual practice, especially among patients requiring maintenance treatment. The present review focuses on management of long-term side effects...
  8. ncbi request reprint Pramipexole in treatment-resistant depression: a 16-week naturalistic study
    Lorenzo Lattanzi
    Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Italy
    Bipolar Disord 4:307-14. 2002
    ..To assess the antidepressant efficacy and tolerability of adjunctive pramipexole, a D2-D3 dopamine agonist, in patients with drug-resistant depression...
  9. ncbi request reprint Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder
    Lee S Cohen
    Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital MGH, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:540-3. 2004
    ..05 for all comparisons, Wilcoxon tests). Intermittent treatment was well tolerated. This preliminary report suggests that premenstrual use of venlafaxine is an efficacious and well-tolerated treatment for premenstrual dysphoric disorder...
  10. ncbi request reprint Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Nerv Ment Dis 195:175-8. 2007
    ..Atypical and melancholic MDD subtypes were not significantly associated with brain WMH. In conclusion, subcortical brain vascular lesions may be more prevalent or severe in MDD with anger attacks...
  11. ncbi request reprint Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide
    Stefano Pini
    Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy
    Int Clin Psychopharmacol 18:15-21. 2003
    ..However, in the subgroup with comorbid panic disorder, paroxetine is more effective than moclobemide in reducing both depressive and anxiety symptoms...
  12. ncbi request reprint The psychotic spectrum: validity and reliability of the Structured Clinical Interview for the Psychotic Spectrum
    A Sbrana
    Department of Psychiatry, University of Pisa, Via Roma 67, 56127 Pisa, Italy
    Schizophr Res 75:375-87. 2005
    ..The SCI-PSY significantly discriminated subjects with any psychiatric diagnosis from controls and subjects with from those without psychotic disorders. The hypothesized structure of the instrument was confirmed empirically...
  13. ncbi request reprint Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment
    Silvana Galderisi
    Department of Psychiatry, University of Naples SUN, Naples, Italy
    Neuropsychobiology 52:83-9. 2005
    ..These results support the hypothesis that the COMT Val(158)Met polymorphism influences executive functions in schizophrenia and the neuromotor performance in the deficit subtype only...
  14. pmc Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia
    Silvana Galderisi
    Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie, 80138 Naples, Italy
    Schizophr Bull 34:393-401. 2008
    ..These findings do not support the hypothesis that DS is the extreme end of a severity continuum within schizophrenia...
  15. ncbi request reprint Depression and renal disease
    Eliana Tossani
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Semin Dial 18:73-81. 2005
    ..Screening for CYP isoenzyme interactions with current medications is also recommended before starting antidepressant treatment...
  16. ncbi request reprint COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study
    Silvana Galderisi
    Department of Psychiatry, University of Naples SUN, Largo Madonna delle Grazie 1, 80138 Naples, Italy
    Schizophr Res 73:27-30. 2005
    ..These results do not support the hypothesis that the COMT Val(158)Met or BDNF C(270)T gene polymorphisms are associated with liability to schizophrenia...
  17. ncbi request reprint Depression and public health: an overview
    Paolo Cassano
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street ACC 812, Boston, MA 02114, USA
    J Psychosom Res 53:849-57. 2002
    ..Programs aimed at improving patient follow-up and the coordination of the primary care intervention with that of specialists have been found to improve patient outcomes and to be cost effective...
  18. ncbi request reprint Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort
    Lori L Davis
    VA Medical Center, Tuscaloosa, AL 35404, USA
    Am J Addict 15:278-85. 2006
    ..048 to <0.0001). They were also less likely to be Hispanic and endorse general medical comorbidities (p = 0.006 and 0.002, respectively)...
  19. ncbi request reprint Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life
    Claudio N Soares
    Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada
    Menopause 13:780-6. 2006
    ..To examine the efficacy and tolerability of escitalopram (ESCIT) compared to estrogen and progestogen therapy (EPT) for the treatment of symptomatic peri- and postmenopausal women...
  20. ncbi request reprint Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort
    Lori L Davis
    VA Medical Center, Tuscaloosa, AL 35404, USA
    Compr Psychiatry 46:81-9. 2005
    ..In conclusion, gender, marital status, age of onset of major depression, functional impairment, and suicide risk factors differ in depressed patients with concurrent SUD symptoms compared to those without SUD comorbidity...